NCT07419932Recruiting
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study
Source: ClinicalTrials.gov · Last updated 19 Feb 2026
Brief summary (registry, in English)
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 6 Feb 2026
- Start date
- Dec 2025
- Primary completion date
- Dec 2028
- Lead sponsor
- Fujian Medical University
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT07419932
What you commit to
- Study type: Observational
- Planned participants: 120
- From Dec 2025 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who refuse tumor tissue biopsy or surgery.
- Prior thyroid or major neck surgery.
- Concurrent active malignancies.
Other illness
- History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan.
- Uncontrolled systemic diseases, including diabetes, hypertension, etc.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Age ≥ 14 years at enrollment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).
- LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board.
- For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team.
- Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Normal function of major organs.
- Written informed consent obtained.
Age in the registry: 14 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Medical University Union Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.